Table S2 from Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation–Related Abscopal ResponsesJames W. Welsh, David S. Hong, Chad Tang et al.|Unknown|2023Cited by 0
Table S3 from Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation–Related Abscopal ResponsesJames W. Welsh, David S. Hong, Hampartsoum B. Barsoumian et al.|Unknown|2023Cited by 0
Table S1 from Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation–Related Abscopal ResponsesJames W. Welsh, David S. Hong, Chad Tang et al.|Unknown|2023Cited by 0
Table S2 from Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation–Related Abscopal ResponsesJames W. Welsh, David S. Hong, Chad Tang et al.|Unknown|2023Cited by 0
Table S1 from Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation–Related Abscopal ResponsesJames W. Welsh, David S. Hong, Chad Tang et al.|Unknown|2023Cited by 0